Department of Retina and Vitreous, Aravind Eye Hospital, Madurai, India.
Int Ophthalmol. 2022 Jan;42(1):323-336. doi: 10.1007/s10792-021-01996-7. Epub 2021 Aug 11.
The pandemic of COVID-19 has been caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Apart from respiratory malfunction, COVID-19 causes a system-wide thromboembolic state, leading to serious cardiovascular, cerebrovascular and peripheral vascular manifestations. However, our knowledge regarding retinal manifestations due to systemic COVID-19 is minimal. This systematic review has comprehensively summarized all retinal manifestations secondary to COVID-19 disease recorded till date since the beginning of the pandemic.
All studies published till November 27, 2020, which have reported retinal manifestations in COVID-19 patients were systematically reviewed using the PRISMA statement.
We included 15 articles: 11 case reports and four cross-sectional case series. The most commonly reported manifestations which did not affect visual acuity were retinal hemorrhages and cotton wool spots. The most common vision threatening manifestation was retinal vein occlusion with associated macular edema. Rarely, patients may also present with retinal arterial occlusions and ocular inflammation. These manifestations may occur from as soon as within a week after the onset of COVID-19 symptoms to more than 6 weeks after.
Mostly causing milder disease, COVID-19 may however lead to severe life-threatening thromboembolic complications, and systemic antithrombotic therapy has been suggested as a prophylactic and therapeutic management strategy for patients affected with serious systemic disease. However, both sick and apparently healthy patients may suffer from various retinal complications which may lead to loss of vision as well. No consensus regarding management of retinal complications with anticoagulants or anti-inflammatory medications have been proposed; however, they may be tackled on individual basis.
COVID-19 大流行是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)病毒引起的。除了呼吸系统功能障碍外,COVID-19 还会引起全身性血栓栓塞状态,导致严重的心血管、脑血管和外周血管表现。然而,我们对全身性 COVID-19 引起的视网膜表现知之甚少。本系统评价全面总结了自大流行开始以来迄今为止记录的所有与 COVID-19 疾病相关的视网膜表现。
使用 PRISMA 声明系统地回顾了截至 2020 年 11 月 27 日发表的所有报告 COVID-19 患者视网膜表现的研究。
我们纳入了 15 篇文章:11 篇病例报告和 4 篇横断面病例系列研究。最常报道的不影响视力的表现是视网膜出血和棉絮斑。最常见的威胁视力的表现是伴有黄斑水肿的视网膜静脉阻塞。很少见的情况下,患者也可能出现视网膜动脉阻塞和眼部炎症。这些表现可能发生在 COVID-19 症状出现后 1 周内至 6 周以上。
COVID-19 主要引起较轻的疾病,但可能导致严重的威胁生命的血栓栓塞并发症,全身性抗血栓治疗已被建议作为严重全身疾病患者的预防和治疗管理策略。然而,患病和看似健康的患者都可能患有各种视网膜并发症,从而导致视力丧失。目前还没有提出关于抗凝剂或抗炎药物治疗视网膜并发症的共识;然而,它们可能需要根据个体情况进行处理。